Sentivera Founded with $76M Immunology Asset from Haisco
Published on · Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowPopulation Health Partners and ARCH Venture Partners have established Sentivera, a US biotech, following a $76 million upfront payment to Haisco Pharmaceutical for an immunology asset. The total deal could exceed $1.5 billion with additional milestone payments. Haisco’s asset is aimed at treating type 2 inflammatory diseases and has recently received authorization to enter clinical trials in China. This investment reflects an increasing trend of collaboration between Chinese drug developers and US pharmaceutical companies, which could impact future market dynamics for biotech investments.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
